Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00573404
Recruitment Status : Terminated (slow accrual)
First Posted : December 14, 2007
Last Update Posted : November 16, 2011
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jordan Berlin, Vanderbilt-Ingram Cancer Center

Brief Summary:

RATIONALE: Imatinib mesylate and sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate given together with sunitinib in treating patients with gastrointestinal stromal tumors.

Condition or disease Intervention/treatment Phase
Gastrointestinal Stromal Tumor Drug: imatinib mesylate Drug: sunitinib malate Other: pharmacological study Phase 1

Detailed Description:


  • To determine the maximum tolerated dose of imatinib mesylate in combination with sunitinib malate in patients with gastrointestinal stromal tumors.
  • To determine the toxicity of this regimen in these patients.
  • To determine the antitumor activity in patients treated with this regimen.

OUTLINE: This is a dose-escalation study of imatinib mesylate.

Patients receive oral sunitinib malate once daily on days 1-14 in course 1 and on days 1-42 in all subsequent courses. Beginning in course 2, patients also receive oral imatinib mesylate once or twice daily on days 1-42. Courses repeat every 6 weeks in the absence of unacceptable toxicity.

Blood samples are collected on day 15 and day 43 for pharmacokinetics.

After completion of study treatment, patients are followed every 6 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors
Study Start Date : July 2007
Actual Primary Completion Date : September 2009
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Experimental: Therapeutic Intervention Drug: imatinib mesylate
will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
Other Name: None noted
Drug: sunitinib malate
Not specified
Other Name: none noted
Other: pharmacological study
Not specified
Other Name: Not noted

Primary Outcome Measures :
  1. Maximum tolerated dose of imatinib mesylate in combination with sunitinib malate [ Time Frame: at 6 weeks ]

Secondary Outcome Measures :
  1. Toxicity profile as assessed by NCI CTCAE v3.0 [ Time Frame: every 6 weeks ]
  2. Pharmacokinetics [ Time Frame: days 15 & 43 ]
  3. Preliminary data on anti-tumor activity of these drugs as assessed by RECIST [ Time Frame: 18 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Biopsy proven gastrointestinal stromal tumor
  • Patients previously treated with imatinib mesylate must have documented progression of disease

    • Untreated disease allowed
  • Must have ≥ 1 measurable lesion by RECIST
  • No history of or known brain metastases, spinal cord compression,carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan


  • ECOG performance status 0-2
  • ANC ≥ 1,500/μL
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 150,000/μL
  • Total serum bilirubin ≤ 2.0 mg/dL
  • Serum calcium ≤ 12.0 mg/dL
  • Serum creatinine ≤ 1.8 mg/dL
  • AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if liver function abnormalities are due to underlying malignancy)
  • Able to take oral medications
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No grade 3 hemorrhage within the past 4 weeks
  • No myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism within the past 6 months
  • No ongoing cardiac dysrhythmias ≥ grade 2
  • No prolonged QTc interval on baseline EKG
  • No hypertension that cannot be controlled by medications (BP > 150/100 mm Hg, despite medical therapy)
  • No pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
  • No known HIV or AIDS-related illness or other active infection
  • No other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator, preclude study entry
  • No malabsorption syndrome
  • No prior intolerance of imatinib mesylate or toxicity necessitating dose modification
  • No prior intolerance of sunitinib malate or toxicity necessitating dose modification


  • Recovered from all acute toxic effects of prior chemotherapy, radiotherapy, or surgical procedures
  • No major surgery or radiotherapy within the past 4 weeks
  • No concurrent treatment on another clinical trial, except supportive care trials or non-treatment trials (e.g., quality of life)
  • No concurrent ketoconazole and other agents known to induce CYP3A4
  • No concurrent theophylline or phenobarbital and/or other agents metabolized by the cytochrome P450 system
  • No ongoing therapeutic doses of coumadin, except low-dose oral coumadin up to 2 mg once daily for thrombosis prophylaxis
  • No concurrent Hypericum perforatum (St. John's wort) or other herbal medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00573404

United States, Tennessee
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States, 37064
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States, 37064
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838
Sponsors and Collaborators
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Jordan D. Berlin, MD Vanderbilt-Ingram Cancer Center
Principal Investigator: Charles D. Blanke, MD, FACP OHSU Knight Cancer Institute
Principal Investigator: Emily Chan, MD, PhD Vanderbilt-Ingram Cancer Center

Responsible Party: Jordan Berlin, Professor of Medicine; Clinical Director, GI Oncology Program; Director, Phase I Program; Medical Director, Clinical Trials Shared Resources; Medical Oncologist, Vanderbilt-Ingram Cancer Center Identifier: NCT00573404     History of Changes
Obsolete Identifiers: NCT00495001
Other Study ID Numbers: VICC GI 0621
P30CA068485 ( U.S. NIH Grant/Contract )
First Posted: December 14, 2007    Key Record Dates
Last Update Posted: November 16, 2011
Last Verified: November 2011

Keywords provided by Jordan Berlin, Vanderbilt-Ingram Cancer Center:
gastrointestinal stromal tumor

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors